Prof Nicholas Finer

Prof Nick FinerTel: 020 3447 9419
Fax: 020 3447 9218
Email: nicholas.finer@uclh.nhs.uk

Location:
University College Hospital

Specialities:
The UCLH centre for weight loss, metabolic and endocrine surgery

Professional background

Prof. Finer obtained a degree in Biochemistry at the University of London, and qualified in Medicine at University College Hospital, London. Further postgraduate training in general (internal) medicine at St George's and St James' Hospitals, London, then Guy's Hospital preceded his appointment from 1988-2002 as Consultant Physician with a special interest in Endocrinology at Luton and Dunstable. In 2002 Prof. Finer moved to University of Cambridge School of Medicine as a senior research associate, honorary consultant endocrinologist and clinical director of the Wellcome Trust Clinical Research Facility. He moved to UCLH in 2008 and holds an honorary chair at University College London (and Robert Gordon University, Aberdeen).  He is chair of the Education and Management Task Force of the International Association for the Study of Obesity, and the English Experts in Severe and Complex Obesity and editor of the journal Clinical Obesity.

Research interests

Professor Finer is a specialist in obesity medicine and has been involved with medical, pharmacological and surgical management of obesity and its complications.  He works as part of a multidisciplinary team of surgeons, physicians, dietitians, specialist nurses and psychologists within the UCLH Weight  Loss Metabolic and Obesity Surgery service.

Publications

  • IC Packianathan, NJ Fuller, DB Peterson, A Wright, WA Coward, N Finer. Use of a reference four-component model to evaluate the ability of alternative methods and prediction techniques to estimate body composition in Type 2 diabetes and its changes following insulin treatment. Int J Body Comp Research 2005;2 (4): 141-148.
  • Tuthill A, Slawik H, O’Rahilly, S, Finer N. Psychiatric co-morbidities in patients attending specialist obesity services in the UK. Quarterly Journal of Medicine 2006: 99:317-325
  • Lean MEJ & Finer N. ABC of obesity. Management: Part II—Drugs. BMJ  2006;333:794-797
  • Torp-Pedersen C, Caterson I, Coutinho W, Finer N, et al.. Cardiovascular Responses to Weight Management and Sibutramine in High-Risk Subjects – An Analysis from the SCOUT Trial. European Heart Journal 2007;28:2915-23
  • Levy P, Fried M, Santini F, Finer N. The comparative effects of bariatric surgery on body weight and type 2 diabetes: a review of the literature. Obesity Surgery 2007,17:1248-56.
  • Wolf AM, Finer N et al. PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: Baseline Health and Health Care. Utilization of the US Sample. Diabetes, Obesity Metabolism. 2008
  • Napolitano A, Miller SR, Murgatroyd PR, Coward WA, Wright A, Finer N, et al. Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity 2008;16:191-8
  • Counterweight Project Team. Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. Br J Gen Practice, 2008.
  • James WPT, Caterson I, Coutinho W, Finer N et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese. New Engl J Med. 2010 363: 1905-17
  • Falaschetti E, Aroon D. Hingorani AD, Jones A, Charakida M, Finer N, Whincup P, Lawlor DA, Smith GD, Sattar N, Deanfield JE. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children European Heart Journal 2010 (epub 23.10.2010)
  • Aronne LJ, Finer N et al. Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance. Obesity (Silver Spring). 2011 Jul;19(7):1404-14.
  • Louise A. Savory, Catherine J., Kerr, Paul, Whiting, Nicholas, Finer, Jane, McEneny, Ashton T. Selenium Supplementation & Exercise: Effect on Oxidant Stress in Overweight Adults. Obesity in press March 2011
  • Astrup A, Al Hakim M, Carraro R, Finer N et al. Sustained Weight Loss with Diet and Liraglutide for Obesity: A 52-week Dose-ranging Randomized. Int J Obesity 2011 epub.
  • Counterweight Project Team. The implementation of the Counterweight Programme in Scotland, UK, Family Practice 2011. Epub 2011.
  • Tsigos C, Hainer V, Basdevant A, Finer N et al. Criteria for EASO-Collaborating Centres for Obesity Management. Obes Facts 2011;4:329–333.